In vitro synergistic effect of fluoroquinolone analogues in combination with artemisinin against Plasmodium falciparum; Their antiplasmodial action in rodent malaria model

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Agarwal, Drishti ^a,c   Sharma, Manish ^b   Dixit, Sandeep K ^a   Dutta, Roshan K ^c   Singh, Ashok K ^b   Gupta, Rinkoo D ^c   Awasthi, Satish K ^a  

^a Chemical Biology Laboratory   (India)

^b UNIVERSITY OF DELHI   (India)

^c SOUTH ASIAN UNIVERSITY   (India)

Author keywords

antiplasmodial activity; artemisinin; Fluoroquinolone derivatives; isobologram

Indexed keywords

ARTEMISININ; COMPOUND 10; COMPOUND 12; COMPOUND 18; NORFLOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MALE; MOUSE; NONHUMAN; PHARMACOPHORE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM 3D7; ANIMAL; CELL CULTURE; DRUG EFFECTS; ERYTHROCYTE; HUMAN; PARASITOLOGY; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CELLS, CULTURED; DRUG SYNERGISM; ERYTHROCYTES; FLUOROQUINOLONES; HUMANS; MICE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 84928731459     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0561-2     Document Type: Article

References (35)

1. Kim Y, Schneider KA. Evolution of drug resistance in malaria parasite populations. Nature Education Knowledge. 2013;4:6.
2. Hastings IM. The origins of antimalarial drug resistance. Trends Parasitol. 2004;20:512-8.
3. WHO. Emergency response to artemisinin resistance in the Greater Mekong subregion: regional framework for action 2013-2015. Geneva: World Health Organization; 2013.
4. Fairhurst RM, Nayyar GM, Breman JG, Hallett R, Vennerstrom JL, Duong S, et al. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg. 2012;87:231-41.
5. Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, Nyandigisi A, et al. Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis. 2012;12:888-96.
6. Mita T, Tanabe K. Evolution of Plasmodium falciparum drug resistance: implications for the development and containment of artemisinin resistance. Jpn J Infect Dis. 2012;65:465-75.
7. Peters W. Plasmodium: resistance to antimalarial drugs. Ann Parasitol Hum Comp. 1990;65:103-6.
8. Mahmoudi N, Ciceron L, Franetich JF, Farhati K, Silvie O, Eling W, et al. In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp. Antimicrob Agents Chemother. 2003;47:2636-9.
9. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP. 1, 8-Naphthyridine derivatives: a new class of chemotherapeutic agents. J Med Pharm Chem. 1962;91:1063-5.
10. Andriole VT. The quinolones: past, present, and future. Clin Infect Dis. 2005;41:113-9.
11. Beteck RM, Smit FJ, Haynes RK, N'Da DD. Recent progress in the development of anti-malarial quinolones. Malar J. 2014;13:339.
12. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336-45.
13. Rodrigues T, Prudencio M, Moreira R, Mota MM, Lopes F. Targeting the liver stage of malaria parasites: a yet unmet goal. J Med Chem. 2012;55:995-1012.
14. Salzer W, Andersag THH. A new type of compounds active against avian malaria. Chem Ber. 1948;81:12-9.
15. Krishna S, Davis TME, Chan PCY, Wells RA, Robson KJH. Ciprofloxacin and malaria. Lancet. 1988;1:1231-2.
16. Hamzaha J, Skinner-Adams T, Davis TME. In vitro antimalarial activity of trovafloxacin, a fourth-generation fluoroquinolone. Acta Trop. 2000;74:39-42.
17. Sarma PS. Norfloxacin: a new drug in the treatment of falciparum malaria. Ann Intern Med. 1989;111:336-7.
18. Salmon D, Deloron P, Gaudin C, Malhotra K, Lebras J, Pocidalo JJ. Activities of pefloxacin and ciprofloxacin against experimental malaria in mice. Agents Chemother. 1990;34:2327-30.
19. Watt G, Shanks GD, Edstein MD, Pavanand K, Webster HK. Ciprofloxacin treatment of drug-resistant falciparum malaria. J Infect Dis. 1991;164:602-4.
20. Dixit SK, Mishra N, Sharma M, Singh S, Agarwal A, Awasthi SK, et al. Synthesis and in vitro antiplasmodial activities of fluoroquinolone analogs. Eur J Med Chem. 2012;51:52-9.
21. Fivelman QL, Adagu IS, Warhurst DC. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother. 2004;48:4097-102.
22. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis. 1978;137:122-30.
23. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1.
24. Mishra LC, Bhattacharya A, Bhasin VK. Antiplasmodial interactions between artemisinin and triclosan or ketoconazole combinations against blood stages of Plasmodium falciparum in vitro. Am J Trop Med Hyg. 2007;76:497-501.
25. Bhattacharya A, Mishra LC, Bhasin VK. In vitro activity of artemisinin in combination with clotrimazole or heat-treated amphotericin B against Plasmodium falciparum. Am J Trop Med Hyg. 2008;78:721-8.
26. Ryley JF, Peters W. The antimalarial activity of some quinolone esters. Ann Trop Med Parasitol. 1970;84:209-22.
27. Peters W. Drug resistance in Plasmodium berghei Vincke and Lips, 1948. I Chloroquine resistance Exp Parasitol. 1965;17:80-9.
28. Yadav N, Dixit SK, Bhattacharya A, Mishra LC, Sharma M, Awasthi SK, et al. Antimalarial activity of newly synthesized chalcone derivatives in vitro. Chem Biol Drug Des. 2012;80:340-7.
29. Cazelles J, Robert A, Meunier B. Alkylation of heme by artemisinin, an antimalarial drug. Comptes Rendus de l'Académie des Sciences Série IIC-Chimie. 2001;4:85-9.
30. Eckstein-Ludwig U, Webb RJ, van Goethem IDA, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of plasmodium falciparum. Nature. 2003;424:957-61.
31. Hartwig CL, Rosenthal AS, Dangelo J, Griffin CE, Posner GH, Cooper RA. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem Pharmacol. 2009;77:322-36.
32. Biagini GA, Fisher N, Shone AE, Mubaraki MA, Srivastava A, Hill A, et al. Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proc Nat Acad Sci USA. 2012;109:8298-303.
33. Francia MC, Striepen B. Cell division in apicomplexan parasites. Nat Rev Microbiol. 2014;12:125-36.
34. García-Estrada C, Prada CF, Fernández-Rubio C, Rojo-Vázquez F, Balaña-Fouce R. DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery. Proc Biol Sci. 2010;277:1777-87.
35. Wells TN, Alonso PL, Gutteridge WE. New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov. 2009;8:879-91.